Implications of Epstein-Barr Virus (EBV)-induced carcinogenesis on cutaneous inflammation and carcinogenesis: Evidence of recurring patterns of angiogenesis and signal transduction

Journal of Investigative Dermatology

Volumn 124, Issue 5, 2005, Pages

  Arbiser, Jack L ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; B RAF KINASE; BORTEZOMIB; CROSS REACTING ANTIGEN; EBSELEN; EPSTEIN BARR VIRUS ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P16INK4A; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SORAFENIB;

ANGIOGENESIS; BASAL CELL CARCINOMA; BURKITT LYMPHOMA; CANCER CELL; CARCINOGENESIS; ENZYME ACTIVATION; EPSTEIN BARR VIRUS; HUMAN; MELANOMA; NOTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN INFLAMMATION; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; VIRUS INFECTION;

EID: 18244387688     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2005.23695.x     Document Type: Note

References (15)

1. Aggarwal S, Takada Y, Singh S, Myers JN, Aggarwal BB: Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappa B signalling (Vol 111, p 679, 2004). Int J Cancer 112:1086, 2004
2. Ahmad N, Gupta S, Mukhtar H: Green tea polyphenol epigallocatechin-3- gallate differentially modulates nuclear factor kappaB in cancer cells versus normal cells. Arch Biochem Biophys 376:338-346, 2000
3. Arbiser JL: Molecular regulation of angiogenesis and tumorigenesis by signal transduction pathways: Evidence of predictable and reproducible patterns of synergy in diverse neoplasms. Semin Cancer Biol 14:81-91, 2004
4. Arbiser JL, Klauber N, Rohan R, et al: Curcumin is an in vivo inhibitor of angiogenesis. Mol Med 4:376-383, 1998
5. Barlogie B, Shaughnessy J, Tricot G, et al: Treatment of multiple myeloma. Blood 103:20-32, 2004
6. Cerimele F, Battle T, Lynch R, et al: Reactive oxygen signaling and MAPK activation distinguish. Epstein-Barr Virus (EBV)-positive verus EBV-negative Burkitt lymphoma. Proc Natl Acad Sci USA 102:175-179, 2004
7. Cohen C, Zavala-Pompa A, Sequeria JH, et al: Mitogen-activated protein kinase activation is an early event in melanama progression. Clin Cancer Res 8:3728-3733, 2002
8. Govindarajan B, Bai X, Cohn C, et al: Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinas (MAPKK) signaling. J Biol Chem 278:9790-9795, 2003
9. Govindarajan B, Klafter R, Miller MS, et al: Reactive oxygen-induced carcinogenesis causes hypermethylation of p16(Ink4a) and activation of MAP kinase. Mol Med 8:1-8, 2002
10. Hussussian CJ, Struewing JP, Goldstein AM, et al: Germline p16 mutations in familial melanoma. Nat Genet 8:15-21, 1994
11. Jagannath S, Barlogie B, Berenson J, et al: A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127:165-172, 2004
12. Liu A, Arbiser JL, Holmgren A, Klein G, Klein E: PSK and Trx80 inhibit B cell growth in EBV infected cord blood rnononuclear cells through T cells activated by the monocyte products IL15 and IL12. Blood 105:1606-1613, 2005
13. McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA: Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med 11:85-89, 2005
14. Tsao H, Sober AJ: Ultraviolet radiation and malignant melanoma. Clin Dermatol 16:67-73, 1998
15. Ziegler A, Leffell DJ, Kunala S, et al: Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci USA 90:4216-4220, 1993